Literature DB >> 24118736

Association of run-in periods with weight loss in obesity randomized controlled trials.

O Affuso1, K A Kaiser, T L Carson, K H Ingram, M Schwiers, H Robertson, F Abbas, D B Allison.   

Abstract

Study-level design characteristics that inform the optimal design of obesity randomized controlled trials (RCTs) have been examined in few studies. A pre-randomization run-in period is one such design element that may influence weight loss. We examined 311 obesity RCTs published between 1 January 2007 and 1 July 2009 that examine d weight loss or weight gain prevention as a primary or secondary end-point. Variables included run-in period, pre-post intervention weight loss, study duration (time), intervention type, percent female and degree of obesity. Linear regression was used to estimate weight loss as a function of (i) run-in (yes/no) and (ii) run-in, time, percent female, body mass index and intervention type. Interaction terms were also examined. Approximately 19% (18.6%) of the studies included a run-in period, with pharmaceutical studies having the highest frequency. Although all intervention types were associated with weight loss (Mean = 2.80 kg, SD = 3.52), the inclusion of a pre-randomization run-in was associated with less weight loss (P = 0.0017) compared with studies that did not include a run-in period. However, this association was not consistent across intervention types. Our results imply that in trials primarily targeting weight loss in adults, run-in periods may not be beneficial for improving weight loss outcomes in interventions.
© 2013 The Authors. obesity reviews © 2013 International Association for the Study of Obesity.

Entities:  

Keywords:  Obesity; randomized clinical trials; run-in periods

Mesh:

Year:  2013        PMID: 24118736      PMCID: PMC3885242          DOI: 10.1111/obr.12111

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  8 in total

Review 1.  Treatment of obesity: an update on anti-obesity medications.

Authors:  A Halpern; M C Mancini
Journal:  Obes Rev       Date:  2003-02       Impact factor: 9.213

2.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  Ann Intern Med       Date:  2010-03-24       Impact factor: 25.391

3.  Direct effect on validity of response run-in selection in clinical trials.

Authors:  Vance W Berger; Azadeh Rezvani; Vanessa A Makarewicz
Journal:  Control Clin Trials       Date:  2003-04

4.  Long-term weight loss with sibutramine: a randomized controlled trial.

Authors:  A Wirth; J Krause
Journal:  JAMA       Date:  2001-09-19       Impact factor: 56.272

5.  Run-in periods in randomized trials: implications for the application of results in clinical practice.

Authors:  A Pablos-Méndez; R G Barr; S Shea
Journal:  JAMA       Date:  1998-01-21       Impact factor: 56.272

6.  Pretreatment weight change is associated with obesity treatment outcomes.

Authors:  Delia Smith West; Jean Harvey-Berino; Rebecca A Krukowski; Joan M Skelly
Journal:  Obesity (Silver Spring)       Date:  2011-02-17       Impact factor: 5.002

Review 7.  Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis.

Authors:  A N Fabricatore; T A Wadden; R H Moore; M L Butryn; E A Gravallese; N E Erondu; S B Heymsfield; A M Nguyen
Journal:  Obes Rev       Date:  2009-03-06       Impact factor: 9.213

8.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Authors:  F Xavier Pi-Sunyer; Louis J Aronne; Hassan M Heshmati; Jeanne Devin; Julio Rosenstock
Journal:  JAMA       Date:  2006-02-15       Impact factor: 56.272

  8 in total
  8 in total

1.  Effectiveness of "run-ins" at predicting adherence in a behavioral weight loss efficacy trial.

Authors:  Tricia M Leahey; Loneke T Blackman Carr; Zeely Denmat; Denise Fernandes; Amy A Gorin
Journal:  Contemp Clin Trials       Date:  2022-01-08       Impact factor: 2.226

2.  Pretreatment and During-Treatment Weight Trajectories in Black and White Women.

Authors:  Camille R Schneider-Worthington; Amber W Kinsey; Fei Tan; Sheng Zhang; Alena C Borgatti; Andrea L Davis; Gareth R Dutton
Journal:  Am J Prev Med       Date:  2022-07       Impact factor: 6.604

Review 3.  Rigorous control conditions diminish treatment effects in weight loss-randomized controlled trials.

Authors:  J A Dawson; K A Kaiser; O Affuso; G R Cutter; D B Allison
Journal:  Int J Obes (Lond)       Date:  2015-10-09       Impact factor: 5.095

4.  Identifying Factors Associated With Dropout During Prerandomization Run-in Period From an mHealth Physical Activity Education Study: The mPED Trial.

Authors:  Yoshimi Fukuoka; Caryl Gay; William Haskell; Shoshana Arai; Eric Vittinghoff
Journal:  JMIR Mhealth Uhealth       Date:  2015-04-13       Impact factor: 4.773

5.  Randomized controlled trials: who fails run-in?

Authors:  Judy R Rees; Leila A Mott; Elizabeth L Barry; John A Baron; Jane C Figueiredo; Douglas J Robertson; Robert S Bresalier; Janet L Peacock
Journal:  Trials       Date:  2016-07-29       Impact factor: 2.279

6.  Randomized clinical trials with run-in periods: frequency, characteristics and reporting.

Authors:  David Ruben Teindl Laursen; Asger Sand Paludan-Müller; Asbjørn Hróbjartsson
Journal:  Clin Epidemiol       Date:  2019-02-11       Impact factor: 4.790

7.  Similar weight loss and maintenance in African American and White women in the Improving Weight Loss (ImWeL) trial.

Authors:  Amber W Kinsey; Marissa A Gowey; Fei Tan; Dali Zhou; Jamy Ard; Olivia Affuso; Gareth R Dutton
Journal:  Ethn Health       Date:  2018-07-02       Impact factor: 2.772

8.  Assessing risk of bias: a proposal for a unified framework for observational studies and randomized trials.

Authors:  Hendrika J Luijendijk; Matthew J Page; Huibert Burger; Xander Koolman
Journal:  BMC Med Res Methodol       Date:  2020-09-23       Impact factor: 4.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.